Initiation of dolutegravir vs. efavirenz on 12- and 24-month retention and viral suppression: a target trial emulation
Initiation of dolutegravir led to an appreciable increase in retention and viral suppression over 24 months when compared to efavirenz. Dolutegravir may lead to increases in long-term retention.
Authors
- Bridgette Goeieman
- Amy Zheng (ORCID: https://orcid.org/0009-0004-4051-2796)
- Mhairi Maskew (ORCID: https://orcid.org/0000-0003-4238-0200)
- Eleanor J. Murray (ORCID: https://orcid.org/0000-0003-0043-4901)
- François Venter (ORCID: https://orcid.org/0000-0002-4157-732X)
- Jacob Bor (ORCID: https://orcid.org/0000-0002-5112-8536)
- Alana T. Brennan (ORCID: https://orcid.org/0000-0002-7746-0668)
- Matthew P. Fox (ORCID: https://orcid.org/0000-0001-9887-0634)
- Pedro T. Pisa (ORCID: https://orcid.org/0000-0001-5188-5660)
- Emma M. Kileel (ORCID: https://orcid.org/0000-0003-0557-2035)
- Ross Greener (ORCID: https://orcid.org/0000-0001-8997-8977)
Institutions
- Boston University (US)
- University of the Witwatersrand (ZA)
- Faculty of Public Health (GB)
Publication Details
- Journal
- Infectious Diseases
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1080/23744235.2025.2557628
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00